PHILM Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €15.20 |
| 52 Week High | €15.20 |
| 52 Week Low | €15.20 |
| Beta | 0.15 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHILM | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.5% | -0.3% |
| 1Y | n/a | -16.7% | 8.7% |
Return vs Industry: Insufficient data to determine how PHILM performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how PHILM performed against the UK Market.
Price Volatility
| PHILM volatility | |
|---|---|
| PHILM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: PHILM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHILM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 157 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.
Philogen S.p.A. Fundamentals Summary
| PHILM fundamental statistics | |
|---|---|
| Market cap | €452.97m |
| Earnings (TTM) | -€5.38m |
| Revenue (TTM) | €26.94m |
16.8x
P/S Ratio-84.3x
P/E RatioIs PHILM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHILM income statement (TTM) | |
|---|---|
| Revenue | €26.94m |
| Cost of Revenue | €13.19m |
| Gross Profit | €13.75m |
| Other Expenses | €19.13m |
| Earnings | -€5.38m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 51.05% |
| Net Profit Margin | -19.96% |
| Debt/Equity Ratio | 4.0% |
How did PHILM perform over the long term?
See historical performance and comparison